Welcome to Paid Research Studies


Browse Locations ... United States» ... West Virginia» ... Charleston






  • Condition:   Hypertension
    Interventions:   Drug: Azilsartan Medoxomil;   Drug: Losartan;   Drug: Placebo for Azilsartan Medoxomil;   Drug: Placebo for Losartan
    Sponsor:   Arbor Pharmaceuticals, Inc.
    Recruiting - verified February 2015

  • Condition:   Follicular Lymphoma
    Interventions:   Drug: IPI-145 (duvelisib);   Drug: Placebo;   Drug: Rituximab
    Sponsor:   Infinity Pharmaceuticals, Inc.
    Recruiting - verified February 2015

  • Condition:   Colorectal Cancer
    Interventions:   Biological: cetuximab;   Drug: irinotecan hydrochloride;   Drug: vemurafenib
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI);   Genentech/Roche
    Recruiting - verified February 2015

  • Conditions:   Adult T Acute Lymphoblastic Leukemia;   Childhood T Acute Lymphoblastic Leukemia;   Stage II Childhood Lymphoblastic Lymphoma;   Stage II Contiguous Adult Lymphoblastic Lymphoma;   Stage II Non-Contiguous Adult Lymphoblastic Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Childhood Lymphoblastic Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Childhood Lymphoblastic Lymphoma;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
    Interventions:   Drug: Bortezomib;   Drug: Cytarabine;   Drug: Vincristine Sulfate;   Drug: Dexamethasone;   Drug: Daunorubicin Hydrochloride;   Drug: Pegaspargase;   Drug: Methotrexate;   Drug: Cyclophosphamide;   Drug: Mercaptopurine;   Drug: Doxorubicin Hydrochloride;   Drug: Thioguanine;   Drug: Hydrocortisone Sodium Succinate;   Drug: Ifosfamide;   Drug: Leucovorin Calcium;   Drug: Etoposide;   Radiation: Radiation Therapy;   Other: Laboratory Biomarker Analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified January 2015

  • Conditions:   Adult B Acute Lymphoblastic Leukemia;   Childhood B Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Lymphoblastic Leukemia
    Interventions:   Drug: Dexamethasone;   Drug: Vincristine Sulfate;   Drug: Pegaspargase;   Drug: Mitoxantrone Hydrochloride;   Drug: Methotrexate;   Drug: Therapeutic Hydrocortisone;   Drug: Cytarabine;   Drug: Leucovorin Calcium;   Drug: Cyclophosphamide;   Drug: Etoposide;   Drug: Asparaginase;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Biological: Blinatumomab;   Drug: Mercaptopurine;   Drug: Thioguanine;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified December 2014

  • Condition:   Critical Limb Ischemia
    Interventions:   Procedure: Open surgical revascularization;   Device: Endovascular revascularization
    Sponsors:   New England Research Institutes;   Brigham and Women's Hospital;   Massachusetts General Hospital;   Boston Medical Center;   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting - verified November 2014

  • Conditions:   Atrial Fibrillation;   Atrial Flutter
    Interventions:   Drug: Metoprolol;   Drug: Diltiazem
    Sponsor:   CAMC Health System
    Recruiting - verified February 2015

  • Conditions:   Estrogen Receptor Positive;   HER2/Neu Positive;   Progesterone Receptor Positive;   Stage IB Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
    Interventions:   Drug: Docetaxel;   Drug: Carboplatin;   Biological: Trastuzumab;   Biological: Pertuzumab;   Drug: Goserelin Acetate;   Procedure: Therapeutic Conventional Surgery;   Radiation: Whole Breast Irradiation;   Other: Laboratory Biomarker Analysis;   Drug: Aromatase Inhibition Therapy;   Other: Quality-of-Life Assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified February 2015

  • Conditions:   Stage I Chronic Lymphocytic Leukemia;   Stage II Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage IV Chronic Lymphocytic Leukemia
    Interventions:   Drug: Ibrutinib;   Biological: Rituximab;   Drug: Bendamustine Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified December 2014

  • Conditions:   Stage II Contiguous Adult Diffuse Large Cell Lymphoma;   Stage II Non-Contiguous Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma
    Interventions:   Drug: Lenalidomide;   Biological: Rituximab;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Drug: Vincristine Sulfate;   Drug: Prednisone;   Other: Laboratory Biomarker Analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified February 2015

  • Condition:   Prostate Cancer
    Interventions:   Drug: TAK-700;   Drug: Bicalutamide
    Sponsors:   Southwest Oncology Group;   Millennium Pharmaceuticals, Inc.;   National Cancer Institute (NCI)
    Recruiting - verified February 2015

  • Condition:   Pneumonia, Bacterial
    Interventions:   Drug: Amikacin Inhalation Solution (BAY41-6551);   Drug: Aerosolized Placebo
    Sponsors:   Bayer;   Nektar Therapeutics
    Recruiting - verified March 2015

  • Conditions:   Recurrent Melanoma;   Stage IIIA Skin Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
    Interventions:   Biological: Ipilimumab;   Biological: Recombinant Interferon Alfa-2b;   Other: Laboratory Biomarker Analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified November 2014

  • Condition:   Atrial Fibrillation
    Intervention:   Other: Patients with Atrial Fibrillation
    Sponsors:   Janssen Scientific Affairs, LLC;   Duke Clinical Research Institute
    Recruiting - verified February 2015

  • Condition:   Breast Cancer
    Interventions:   Drug: anastrozole;   Drug: everolimus;   Drug: exemestane;   Drug: goserelin acetate;   Drug: letrozole;   Drug: leuprolide acetate;   Drug: tamoxifen citrate;   Other: placebo
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified February 2015

  • Condition:   Acute Coronary Syndrome
    Interventions:   Drug: alirocumab SAR236553 (REGN727);   Other: placebo
    Sponsors:   Sanofi;   Regeneron Pharmaceuticals
    Recruiting - verified February 2015

  • Conditions:   Clear Cell Renal Cell Carcinoma;   Recurrent Renal Cell Carcinoma;   Stage IV Renal Cell Cancer
    Interventions:   Drug: Pazopanib Hydrochloride;   Other: Placebo;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Other: Pharmacological Study
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified January 2015

  • Conditions:   Abdominal Aortic Aneurysm;   Aorto-iliac Aneurysm
    Intervention:   Device: Iliac Leg Graft
    Sponsor:   Cook
    Recruiting - verified February 2015

  • Conditions:   Stroke;   Atrial Fibrillation
    Intervention:  
    Sponsor:   Boehringer Ingelheim
    Recruiting - verified February 2015

  • Conditions:   Adult Acute Megakaryoblastic Leukemia;   Adult Acute Monoblastic Leukemia;   Adult Acute Monocytic Leukemia;   Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11;   Adult Acute Myeloid Leukemia With Maturation;   Adult Acute Myeloid Leukemia With Minimal Differentiation;   Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11;   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1;   Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL;   Adult Acute Myeloid Leukemia Without Maturation;   Adult Acute Myelomonocytic Leukemia;   Adult Erythroleukemia;   Adult Pure Erythroid Leukemia;   Childhood Acute Erythroid Leukemia;   Childhood Acute Megakaryoblastic Leukemia;   Childhood Acute Monoblastic Leukemia;   Childhood Acute Monocytic Leukemia;   Childhood Acute Myeloid Leukemia With Maturation;   Childhood Acute Myeloid Leukemia Without Maturation;   Childhood Acute Myelomonocytic Leukemia;   Untreated Adult Acute Myeloid Leukemia;   Untreated Childhood Myeloid Neoplasm
    Interventions:   Drug: Asparaginase;   Drug: Daunorubicin Hydrochloride;   Drug: Mitoxantrone Hydrochloride;   Drug: Sorafenib Tosylate;   Drug: Cytarabine;   Drug: Etoposide;   Drug: Bortezomib;   Other: Pharmacological Study;   Other: Laboratory Biomarker Analysis;   Other: Questionnaire Administration;   Other: Quality-of-Life Assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified October 2014

  • Conditions:   Recurrent Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
    Interventions:   Biological: Ipilimumab;   Biological: Recombinant Interferon Alfa-2b;   Other: Quality-of-Life Assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified November 2014

  • Conditions:   Estrogen Receptor Positive;   HER2/Neu Negative;   Progesterone Receptor Positive;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
    Interventions:   Drug: Systemic Chemotherapy;   Drug: Tamoxifen Citrate;   Drug: Anastrozole;   Drug: Exemestane;   Drug: Letrozole;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified September 2014

  • Condition:   Chronic Myeloid Leukemia
    Intervention:  
    Sponsors:   Bristol-Myers Squibb;   ICON Clinical Research
    Recruiting - verified February 2015

  • Conditions:   Adenocarcinoma of the Gastroesophageal Junction;   Esophageal Adenocarcinoma;   Stage IB Esophageal Cancer;   Stage IIA Esophageal Cancer;   Stage IIB Esophageal Cancer;   Stage IIIA Esophageal Cancer;   Stage IIIB Esophageal Cancer
    Interventions:   Radiation: Radiation Therapy;   Drug: Paclitaxel;   Drug: Carboplatin;   Biological: Trastuzumab;   Procedure: Therapeutic Conventional Surgery;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified January 2015

  • Conditions:   B-cell Childhood Acute Lymphoblastic Leukemia;   Philadelphia Chromosome Positive Childhood Precursor Acute Lymphoblastic Leukemia;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
    Interventions:   Drug: doxorubicin hydrochloride;   Drug: cytarabine;   Drug: vincristine sulfate;   Drug: dexamethasone;   Drug: pegaspargase;   Drug: methotrexate;   Drug: mercaptopurine tablet;   Drug: leucovorin calcium;   Drug: cyclophosphamide;   Drug: thioguanine;   Procedure: quality-of-life assessment;   Other: questionnaire administration;   Other: laboratory biomarker analysis
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified March 2015

  • Conditions:   Light Chain Deposition Disease;   Smoldering Plasma Cell Myeloma
    Interventions:   Drug: Lenalidomide;   Other: Clinical Observation;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified November 2014

  • Condition:   Kidney Cancer
    Interventions:   Drug: everolimus;   Other: placebo
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified February 2015

  • Conditions:   Childhood Infratentorial Ependymoma;   Childhood Supratentorial Ependymoma;   Newly Diagnosed Childhood Ependymoma
    Interventions:   Drug: liposomal vincristine sulfate;   Other: clinical observation;   Radiation: 3-dimensional conformal radiation therapy;   Drug: carboplatin;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: cisplatin;   Other: laboratory biomarker analysis
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified February 2015

  • Conditions:   Pancreatic Acinar Cell Carcinoma;   Pancreatic Ductal Adenocarcinoma;   Pancreatic Intraductal Papillary-Mucinous Neoplasm;   Stage IA Pancreatic Cancer;   Stage IB Pancreatic Cancer;   Stage IIA Pancreatic Cancer;   Stage IIB Pancreatic Cancer
    Interventions:   Drug: Gemcitabine Hydrochloride;   Drug: Erlotinib Hydrochloride;   Radiation: 3-Dimensional Conformal Radiation Therapy;   Radiation: Intensity-Modulated Radiation Therapy;   Drug: Capecitabine;   Drug: Fluorouracil;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified October 2014

  • Conditions:   Hepatoblastoma;   Stage I Childhood Hepatocellular Carcinoma;   Stage II Childhood Hepatocellular Carcinoma;   Stage III Childhood Hepatocellular Carcinoma;   Stage IV Childhood Hepatocellular Carcinoma
    Interventions:   Procedure: Therapeutic Conventional Surgery;   Drug: Cisplatin;   Drug: Fluorouracil;   Drug: Vincristine Sulfate;   Drug: Doxorubicin Hydrochloride;   Drug: Irinotecan Hydrochloride;   Drug: Temsirolimus;   Procedure: Liver Transplantation;   Other: Laboratory Biomarker Analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified October 2014

  • Conditions:   Adult Rhabdomyosarcoma;   Childhood Desmoplastic Small Round Cell Tumor;   Chordoma;   Desmoid Tumor;   Metastatic Childhood Soft Tissue Sarcoma;   Nonmetastatic Childhood Soft Tissue Sarcoma;   Previously Treated Childhood Rhabdomyosarcoma;   Previously Untreated Childhood Rhabdomyosarcoma;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Childhood Soft Tissue Sarcoma;   Stage I Adult Soft Tissue Sarcoma;   Stage II Adult Soft Tissue Sarcoma;   Stage III Adult Soft Tissue Sarcoma;   Stage IV Adult Soft Tissue Sarcoma
    Interventions:   Other: biologic sample preservation procedure;   Other: laboratory biomarker analysis
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified March 2015

  • Conditions:   Anemia;   Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndrome;   Previously Treated Myelodysplastic Syndrome
    Interventions:   Drug: Lenalidomide;   Biological: Epoetin Alfa;   Other: Laboratory Biomarker Analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified November 2014

  • Conditions:   Abdominal Aortic Aneurysms;   Iliac Aneurysms;   Aorto-iliac Aneurysms
    Intervention:   Device: Zenith(R) Low Profile AAA Endovascular Graft
    Sponsor:   Cook
    Recruiting - verified February 2015

  • Conditions:   Recurrent Hypopharyngeal Squamous Cell Carcinoma;   Recurrent Laryngeal Squamous Cell Carcinoma;   Recurrent Laryngeal Verrucous Carcinoma;   Recurrent Lip and Oral Cavity Squamous Cell Carcinoma;   Recurrent Metastatic Squamous Cell Carcinoma to the Neck With Occult Primary;   Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma;   Recurrent Oral Cavity Verrucous Carcinoma;   Recurrent Oropharyngeal Squamous Cell Carcinoma;   Recurrent Salivary Gland Carcinoma;   Salivary Gland Squamous Cell Carcinoma;   Squamous Cell Carcinoma Metastatic to the Neck With Occult Primary;   Stage IV Hypopharyngeal Squamous Cell Carcinoma;   Stage IV Major Salivary Gland Carcinoma;   Stage IVA Laryngeal Squamous Cell Carcinoma;   Stage IVA Laryngeal Verrucous Carcinoma;   Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma;   Stage IVA Major Salivary Gland Carcinoma;   Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma;   Stage IVA Oral Cavity Verrucous Carcinoma;   Stage IVA Oropharyngeal Squamous Cell Carcinoma;   Stage IVB Laryngeal Squamous Cell Carcinoma;   Stage IVB Laryngeal Verrucous Carcinoma;   Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma;   Stage IVB Major Salivary Gland Carcinoma;   Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma;   Stage IVB Oral Cavity Verrucous Carcinoma;   Stage IVB Oropharyngeal Squamous Cell Carcinoma;   Stage IVC Laryngeal Squamous Cell Carcinoma;   Stage IVC Laryngeal Verrucous Carcinoma;   Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma;   Stage IVC Major Salivary Gland Carcinoma;   Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma;   Stage IVC Oral Cavity Verrucous Carcinoma;   Stage IVC Oropharyngeal Squamous Cell Carcinoma;   Tongue Carcinoma;   Untreated Metastatic Squamous Cell Carcinoma to Neck With Occult Primary
    Interventions:   Drug: Docetaxel;   Drug: Cisplatin;   Drug: Carboplatin;   Drug: Fluorouracil;   Biological: Bevacizumab;   Other: Laboratory Biomarker Analysis;   Other: Cytology Specimen Collection Procedure
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified February 2015

  • Conditions:   Cancer Survivor;   Cardiovascular Complications;   Hematopoietic/Lymphoid Cancer;   Unspecified Childhood Solid Tumor, Protocol Specific
    Interventions:   Other: questionnaire administration;   Other: laboratory biomarker analysis
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified March 2015